Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
CNY 42.8
(-0.23%)
CNY 42.8
(-0.23%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.06 Billion CNY | 3.06% |
| 2022 | 1.91 Billion CNY | 11.66% |
| 2021 | 1.71 Billion CNY | -5.71% |
| 2020 | 1.81 Billion CNY | -10.97% |
| 2019 | 2.03 Billion CNY | 27.92% |
| 2018 | 1.59 Billion CNY | 63.47% |
| 2017 | 975.01 Million CNY | 25.83% |
| 2016 | 774.86 Million CNY | 63.95% |
| 2015 | 472.61 Million CNY | 3.72% |
| 2014 | 455.65 Million CNY | 48.64% |
| 2013 | 306.55 Million CNY | 10.81% |
| 2012 | 276.65 Million CNY | 126.69% |
| 2011 | 122.03 Million CNY | 30.72% |
| 2010 | 93.35 Million CNY | 20.84% |
| 2009 | 77.25 Million CNY | 101.33% |
| 2008 | 38.37 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 649.65 Million CNY | -17.53% |
| 2024 Q1 | 442.64 Million CNY | -22.07% |
| 2024 Q2 | 589.52 Million CNY | 33.18% |
| 2023 Q4 | 567.99 Million CNY | 2.38% |
| 2023 FY | 1.96 Billion CNY | 3.06% |
| 2023 Q1 | 409.52 Million CNY | -33.97% |
| 2023 Q2 | 473.56 Million CNY | 15.64% |
| 2023 Q3 | 554.8 Million CNY | 17.16% |
| 2022 FY | 1.91 Billion CNY | 11.66% |
| 2022 Q2 | 415.77 Million CNY | 17.56% |
| 2022 Q4 | 620.19 Million CNY | 18.9% |
| 2022 Q3 | 521.61 Million CNY | 25.46% |
| 2022 Q1 | 353.67 Million CNY | -34.24% |
| 2021 Q3 | 432.23 Million CNY | 40.12% |
| 2021 Q4 | 537.86 Million CNY | 24.44% |
| 2021 FY | 1.71 Billion CNY | -5.71% |
| 2021 Q1 | 433.06 Million CNY | -26.95% |
| 2021 Q2 | 308.48 Million CNY | -28.77% |
| 2020 Q4 | 592.82 Million CNY | 31.81% |
| 2020 Q1 | 266.01 Million CNY | -51.21% |
| 2020 Q3 | 449.74 Million CNY | -11.24% |
| 2020 FY | 1.81 Billion CNY | -10.97% |
| 2020 Q2 | 506.69 Million CNY | 90.48% |
| 2019 Q1 | 452.8 Million CNY | -18.88% |
| 2019 Q3 | 566.7 Million CNY | 19.52% |
| 2019 Q4 | 545.21 Million CNY | -3.79% |
| 2019 FY | 2.03 Billion CNY | 27.92% |
| 2019 Q2 | 474.15 Million CNY | 4.71% |
| 2018 Q2 | 358.21 Million CNY | 46.18% |
| 2018 Q4 | 558.21 Million CNY | 29.11% |
| 2018 FY | 1.59 Billion CNY | 63.47% |
| 2018 Q1 | 245.05 Million CNY | -4.75% |
| 2018 Q3 | 432.37 Million CNY | 20.7% |
| 2017 Q1 | 199.8 Million CNY | -38.79% |
| 2017 FY | 975.01 Million CNY | 25.83% |
| 2017 Q2 | 359.4 Million CNY | 79.88% |
| 2017 Q4 | 257.27 Million CNY | 62.29% |
| 2017 Q3 | 158.52 Million CNY | -55.89% |
| 2016 Q3 | 139.08 Million CNY | -36.7% |
| 2016 Q1 | 89.6 Million CNY | -46.97% |
| 2016 Q4 | 326.43 Million CNY | 134.71% |
| 2016 FY | 774.86 Million CNY | 63.95% |
| 2016 Q2 | 219.73 Million CNY | 145.21% |
| 2015 Q4 | 168.98 Million CNY | 36.24% |
| 2015 Q3 | 124.03 Million CNY | 22.67% |
| 2015 Q2 | 101.11 Million CNY | 28.85% |
| 2015 Q1 | 78.47 Million CNY | -46.61% |
| 2015 FY | 472.61 Million CNY | 3.72% |
| 2014 Q2 | 110.55 Million CNY | 32.41% |
| 2014 FY | 455.65 Million CNY | 48.64% |
| 2014 Q4 | 146.99 Million CNY | 28.26% |
| 2014 Q3 | 114.6 Million CNY | 3.66% |
| 2014 Q1 | 83.49 Million CNY | 16.76% |
| 2013 Q2 | 84.02 Million CNY | 13.98% |
| 2013 Q4 | 71.51 Million CNY | -7.48% |
| 2013 FY | 306.55 Million CNY | 10.81% |
| 2013 Q1 | 73.72 Million CNY | -26.15% |
| 2013 Q3 | 77.29 Million CNY | -8.01% |
| 2012 FY | 276.65 Million CNY | 126.69% |
| 2012 Q2 | 68.93 Million CNY | 60.27% |
| 2012 Q3 | 64.88 Million CNY | -5.88% |
| 2012 Q4 | 99.82 Million CNY | 53.85% |
| 2012 Q1 | 43.01 Million CNY | 27.46% |
| 2011 FY | 122.03 Million CNY | 30.72% |
| 2011 Q4 | 33.74 Million CNY | 12.4% |
| 2011 Q3 | 30.02 Million CNY | -9.56% |
| 2011 Q2 | 33.19 Million CNY | 32.39% |
| 2011 Q1 | 25.07 Million CNY | -23.83% |
| 2010 Q3 | 21.8 Million CNY | 0.0% |
| 2010 FY | 93.35 Million CNY | 20.84% |
| 2010 Q4 | 32.91 Million CNY | 50.93% |
| 2009 FY | 77.25 Million CNY | 101.33% |
| 2008 FY | 38.37 Million CNY | 0.0% |